Trillium Therapeutics (TRIL) is a Canadian biopharmaceutical company developing fusion-proteins targeting CD47, an immune checkpoint inhibitor involved in suppression of the innate immune system (macrophages). If you are new to the CD47 story, I recommend you start here.
Last week, Trillium posted updated data from early phase trials of their lead compound, TTI-621, in various lymphoma subtypes. I previously wrote about TTI-621 and the CD47 pathway and will reserve this article for the discussion of Trillium's updated results. As a reminder, TRIL is evaluating TTI-621 in ongoing trials using two methods of